NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis $2.27 -0.01 (-0.44%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$2.20▼$2.4750-Day Range$2.27▼$3.8952-Week Range$2.15▼$4.75Volume28,047 shsAverage Volume25,466 shsMarket Capitalization$119.13 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Inventiva alerts: Email Address Inventiva MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside648.9% Upside$17.00 Price TargetShort InterestBearish0.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.21) to ($2.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.33 out of 5 starsMedical Sector773rd out of 936 stocksPharmaceutical Preparations Industry358th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingInventiva has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInventiva has received no research coverage in the past 90 days.Read more about Inventiva's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.26% of the outstanding shares of Inventiva have been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 11, which indicates bearish sentiment.Change versus previous monthShort interest in Inventiva has recently increased by 5.66%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IVA. Previous Next 2.5 News and Social Media Coverage News SentimentInventiva has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inventiva this week, compared to 1 article on an average week.MarketBeat Follows1 people have added Inventiva to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.06% of the stock of Inventiva is held by institutions.Read more about Inventiva's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inventiva are expected to decrease in the coming year, from ($2.21) to ($2.34) per share.Read more about Inventiva's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad MarketBeatWe just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.Start Your Risk-Free Trial Here About Inventiva Stock (NASDAQ:IVA)Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More IVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IVA Stock News HeadlinesJuly 25 at 7:21 PM | finanznachrichten.deINVENTIVA: Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 25 at 4:00 PM | globenewswire.comInventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranorJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 19, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces a €20.1 million issuance of royalty certificatesJuly 19, 2024 | globenewswire.comHalf-Year Review of Inventiva's Liquidity Contract with Kepler CheuvreuxJuly 18, 2024 | globenewswire.comInventiva announces a €20.1 million issuance of royalty certificatesJuly 5, 2024 | globenewswire.comInventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial positionJune 21, 2024 | globenewswire.comResults of the votes of the Combined Shareholders' General Meeting of June 20, 2024July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.May 30, 2024 | globenewswire.comCombined General Meeting of June 20, 2024 - Availability of the preparatory documentsMay 28, 2024 | seekingalpha.comAltimmune: A Potential Minor Player In The Massive GLP-1 SpaceMay 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva announces two scientific presentations at the EASL International Liver Congress 2024May 22, 2024 | globenewswire.comInventiva announces two scientific presentations at the EASL International Liver Congress™ 2024May 22, 2024 | finanznachrichten.deINVENTIVA: Inventiva reports 2024 First Quarter Financial Information and provides a corporate updateMay 21, 2024 | globenewswire.comInventiva reports 2024 First Quarter Financial Information¹ and provides a corporate updateMay 16, 2024 | globenewswire.comInventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASHMay 14, 2024 | finance.yahoo.comFull Video Coverage: Investor Engagement in Private vs. Public Markets Panel From IPO Edge Bootcamp at NasdaqMay 13, 2024 | globenewswire.comInventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranorSee More Headlines Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Confirmed)9/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVA CUSIPN/A CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees100Year Founded2011Price Target and Rating Average Stock Price Target$17.00 High Stock Price Target$25.00 Low Stock Price Target$11.00 Potential Upside/Downside+655.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.96 Quick Ratio0.95 Sales & Book Value Annual Sales$18.91 million Price / Sales6.24 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-3.36Miscellaneous Outstanding Shares52,480,000Free Float35,684,000Market Cap$118.08 million OptionableNot Optionable Beta0.97 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Frederic Cren (Age 58)Co-Founder, CEO & Chairman Comp: $519.9kDr. Pierre Broqua Ph.D. (Age 62)Co-Founder, Chief Scientific Officer, Deputy CEO & Director Comp: $449.01kMr. Jean Volatier (Age 59)Deputy GM & CFO Ms. Alice Roudot-Ketelers Pharm.D. (Age 53)Chief Operating Officer Mr. Eric Duranson L.L.M. (Age 50)General Counsel Ms. Nathalie Harroy (Age 57)Head of Human Resources Dr. Michael Cooreman (Age 66)Chief Medical Officer Ms. Pascaline Clerc Ph.D. (Age 44)Executive Vice President of Strategy & Corporate Affairs More ExecutivesKey CompetitorsPureTech HealthNASDAQ:PRTCCOMPASS PathwaysNASDAQ:CMPSTheravance BiopharmaNASDAQ:TBPHHeron TherapeuticsNASDAQ:HRTXOculisNASDAQ:OCSView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 10,490 shares on 5/20/2024Ownership: 0.020%View All Institutional Transactions IVA Stock Analysis - Frequently Asked Questions How have IVA shares performed this year? Inventiva's stock was trading at $4.52 at the beginning of 2024. Since then, IVA shares have decreased by 49.8% and is now trading at $2.27. View the best growth stocks for 2024 here. When did Inventiva IPO? Inventiva (IVA) raised $103 million in an initial public offering (IPO) on Friday, July 10th 2020. The company issued 7,500,000 shares at $13.68 per share. Jefferies, Stifel and Guggenheim Securities served as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IVA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
